Zobrazeno 1 - 10
of 14
pro vyhledávání: '"S. H. Cunningham"'
Autor:
P. N. Tudor, S. H. Cunningham
Publikováno v:
SMPTE Motion Imaging Journal. 113:236-242
Many organizations are contemplating the move to new program-making tools based on generic information technology (IT) equipment. There is remarkable consensus among key manufacturers and end-users that the Advanced Authoring Format (AAF) and related
Autor:
M. M. Brown, Anthony G. McCluskey, Robert J. Mairs, S. H. Cunningham, A. Livingstone, Sean Carlin, T. E. Wheldon, K. Stevenson, Marie Boyd, S. C. Mairs, L. Wilson
Publikováno v:
The Journal of Gene Medicine. 3:165-172
Background Although [I-131]meta-iodobenzylguanidine (MIBG) is currently one of the best agents available for targeted radiotherapy, its use is confined to a few neural crest derived tumours which accumulate the radiopharmaceutical via the noradrenali
Publikováno v:
Current Pharmaceutical Design. 6:1419-1432
For targeted radionuclide therapy to succeed as a single modality treatment, schemes must be devised which will enable the deposition in malignant cells of sterilising doses of radiation. Until such methods have been perfected, it is necessary to com
Autor:
J. B. Neilly, Robert J. Mairs, N. S. Reed, J. Prosser, S. H. Cunningham, A. A. Bolster, T. E. Hilditch, J Owens
Publikováno v:
Nuclear Medicine Communications. 21:437-440
Radioiodinated meta-iodobenzylguanidine (MIBG) is used routinely for imaging and targeted radiotherapy of tumours derived from the neural crest. Since active uptake of MIBG by the noradrenaline transporter (NAT) makes a greater contribution to total
Autor:
Anthony G. McCluskey, Robert J. Mairs, S. H. Cunningham, A. Livingstone, Sean Carlin, T. E. Wheldon, M.M. Brown, Marie Boyd
Publikováno v:
Medical and Pediatric Oncology. 35:708-711
Background The aims of this study were to determine whether the introduction and expression of the noradrenaline transporter (NAT) gene into NAT-negative neuroblastoma cell lines would make them amenable to targeted radiotherapy using [131I]MIBG. Pro
Publikováno v:
British Journal of Cancer
Scopus-Elsevier
Scopus-Elsevier
[131I]meta-iodobenzylguanidine ([131I]MIBG) provides a means of selectively delivering radiation to neuroblastoma cells and is a promising addition to the range of agents used to treat neuroblastoma. As MIBG is now being incorporated into multimodal
Autor:
J Owens, S. H. Cunningham, James A. Russell, Michael R. Zalutsky, Mark N. Gaze, Ganesan Vaidyanathan, Robert J. Mairs, Joseph A. O'Donoghue
Publikováno v:
European Journal of Cancer. 31:576-581
In vitro and in vivo neuroblastoma models were used to determine whether improvements in tumour targeting in vivo and therapeutic efficacy in vitro could result from the use of no-carrier-added (n.c.a.) [131I]MIBG. Results were compared with use of t
Autor:
M M Brown, Marlynne Quigg, Susan C Mairs, Robert J. Mairs, S. H. Cunningham, Marie Boyd, A. Livingstone, W. Nicol Keith, L. Wilson
Publikováno v:
Oncogene. 20(53)
One of the most effective ways to kill cancer cells is by treatment of tumours with radiation. However, the administered dose of radiation to the tumour is limited by normal tissue toxicity. Strategies which decrease normal tissue exposure relative t
Autor:
M, Boyd, R J, Mairs, S H, Cunningham, S C, Mairs, A, McCluskey, A, Livingstone, K, Stevenson, M M, Brown, L, Wilson, S, Carlin, T E, Wheldon
Publikováno v:
The journal of gene medicine. 3(2)
Although [131I]meta-iodobenzylguanidine (MIBG) is currently one of the best agents available for targeted radiotherapy, its use is confined to a few neural crest derived tumours which accumulate the radiopharmaceutical via the noradrenaline transport
Publikováno v:
Cancer gene therapy. 7(12)
To evaluate the potential of the expression of the sodium/iodide symporter (NIS) as a means of targeting radioiodine to tumor cells, we have employed plasmid-mediated transfection of the NIS gene into a range of mammalian cell hosts. We observed perc